Table 1.
Breast cancer patient characteristics (total, n = 569)
| Characteristics | n (%) |
|---|---|
| Age (years) | |
| ≤40 | 48 (8.4) |
| 40–50 | 158 (27.8) |
| 50–60 | 211 (37.1) |
| 60–70 | 100 (17.6) |
| >70 | 52 (9.1) |
| Gender | |
| Female | 566 (99.5) |
| Male | 3 (0.5) |
| ECOG performance status | |
| 0 or 1 | 399 (70.1) |
| 2 | 120 (21.1) |
| Unknown | 50 (8.8) |
| Stage (AJCC eighth edition), anatomic | |
| I | 168 (29.5) |
| IIA/B | 209 (36.7) |
| IIIA/B/C | 87 (15.3) |
| IV | 105 (18.5) |
| Type of anticancer therapy | |
| Cytotoxic chemotherapy | 230 (40.4) |
| Docetaxel/paclitaxel | 109 (19.1) |
| Adriamycin | 45 (7.9) |
| Gemcitabine | 29 (5.1) |
| Vinorelbine | 8 (1.4) |
| CMF | 19 (3.3) |
| Eribulin | 8 (1.4) |
| Clinical trial | 12 (2.0) |
| Non-cytotoxic therapy | 339 (59.6) |
| Endocrine therapy | 316 (55.5) |
| Palbociclib with letrozole | 7 (1.2) |
| Targeted therapy including trastuzumab | 23 (4.0) |